ocgn/old hsgx (ocgn)

[Buckey]

copied out
Investor FAQs
October 2, 2019
Due to the high volume of calls and emails from our shareholders, we wanted to address some
of the most common questions we have received.
Q: What was the date of the merger?
A: The merger was completed after the market closed on Friday, September 27, 2019.
Q: What was the stock price at the close of the merger?
A: Histogenics stock price at the time of closing was $0.1620. After the reverse split, this
translated to $9.72 as the Ocugen share price.
Q: What was the reverse split ratio?
A: Histogenics issued a 1 for 60 reverse split after the market closed on Friday, September 27,
2019. For example, if you owned 6,000 shares of Histogenics stock before the merger, you
would have 100 Ocugen shares after the merger.
Q: How many shares are outstanding?
A: As of the market opening on Monday, September 30, 2019, there were 10 million shares
outstanding. We’ve issued an additional 2.2 million shares to new investors as part of the
Pre-Merger Financing transaction, which results in 12.2 million shares outstanding.
Q: What is the float?
A: As of the market opening on Monday, September 30, 2019, the float is approximately 53%.
With the issuance of the additional shares, the float is approximately 61%.
Q: What is happening with fractional shares?
A: Broadridge Financial Solutions, Inc. will convert the fractional shares into cash and deposit
into the brokerage account. You can find contact information for them at
https://www.broadridge.com
Q: What caused the stock price to drop approximately 70% on the first day of trading?
A: We know of no negative news impacting the Ocugen stock. We believe the stock has been
unduly impacted by retail shareholders selling their position. Management believes in the
intrinsic value of Ocugen and is committed to developing our broad pipeline of innovative
therapies that address rare and underserved eye diseases. We look forward to sharing
more information about our pipeline at both the Cantor Global Healthcare Conference and
Chardan Genetic Medicines Conference, both of which are being webcast. You can sign up
to listen to the presentation through the events lin